Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025European Journal of Preventive Cardiology

Plasma reduction of apolipoprotein C-III with olezarsen leads to significant reductions in postprandial triglyceride levels: Results from a randomized trial

View Full Paper
Ask AI
Bookmark
Share

Authors

JKJordan M. KraaijenhofMPMerel PeletierNNNick S. Nurmohamed

Discussion

Loading...

Member takes

Overview

Randomized trial demonstrates significant reductions in postprandial triglyceride levels, highlighting olezarsen's potential in managing hypertriglyceridemia.

Key Points

  • Olezarsen treatment resulted in a significant 50.1% reduction in postprandial triglyceride levels.
  • Patients treated with olezarsen had a 96.6% decrease in those reaching triglyceride levels indicative of pancreatitis.
  • The study involved 28 patients with fasting triglycerides ≥4 mmol/L, randomized to receive olezarsen or placebo.
  • Olezarsen highlighted as a promising intervention for reducing risks associated with hypertriglyceridemia.

Cite This Study

Kraaijenhof et al. (2025) studied this question.

synapsesocial.com/papers/68c1a3f954b1d3bfb60de19fhttps://doi.org/10.1093/eurjpc/zwaf478
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Appraisal of Olezarsen for Treatment of Hypertriglyceridemia2024 · 2 citations
  2. 2Targeting <i>APOC3</i> with Olezarsen in Moderate Hypertriglyceridemia2025 · 69 citations
  3. 3Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia2022 · 49 citations
  4. 4Olezarsen for Hypertriglyceridemia: A New Therapy Update with Systematic Review and Meta-Analysis2026
  5. 5Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome2024 · 257 citations